MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs

Published on :

MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT), a leading commercial cell-engineering company providing enabling platform technologies to advance innovative cell-based research, as well as next-generation cell therapeutic discovery, development and commercialization, today announced the signing of a strategic platform license (SPL) with Catamaran Bio, Inc.,  a biotechnology company developing novel, off the-shelf chimeric antigen receptor (CAR)-NK cell therapies to treat a broad range of cancers, with a primary focus on solid tumors.

MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases

Published on :

MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Curamys, a South Korean biotechnology company that develops cell & gene therapy using cell fusion technology to treat rare intractable diseases, including Duchenne muscular dystrophy and amyotrophic lateral sclerosis, today announced the signing of a strategic platform license (SPL).

MilliporeSigma invests $286M in new Montgomery County facility

Published on :

International biosciences company MilliporeSigma  is adding 500 new jobs to the Montgomery County region with its upcoming expansion project.
The company, known locally as BioReliance Corporation, is moving into a new 250,000 square-foot space at the Traville Gateway campus in Rockville, where it will retain at least 600 existing workers and add the new full-time positions. The company credits expanding its biosafety testing capacity in the Mid Atlantic due to Montgomery County’s ideal East Coast location and accessibility to Maryland’s highly trained and technical workforce.

American Gene Technologies® Chief Medical Officer Honored by UCSF Endowment for HIV Dermatology and LGBTQ Health Research

Published on :

American Gene Technologies, a clinical-stage biotechnology company based in Rockville, Maryland, congratulates Dr. Marcus Conant and the University of California San Francisco (UCSF) Medical Center’s Department of Dermatology for establishing The Marcus Conant, MD, Endowment for HIV Dermatology and LGBTQ Health.
 
Dr. Conant is American Gene Technologies’ Chief Medical Officer and UCSF’s clinical professor emeritus of dermatology. The endowment named in his honor aims to provide mentorship and support to researchers in HIV-related skin disease and LGBTQ health. Not only will it supply increased funding for researchers early on in their careers, but it will also enable UCSF to remain competitive in recruiting the best and brightest students, residents, and fellows — all with the goal of advancing HIV treatment and LGBTQ health.

Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB

Published on :

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released results from a Phase I study of the investigational inhibitor of apoptosis protein (IAP) antagonist APG-1387 in Chinese patients with chronic hepatitis B (CHB), in an oral presentation at the 73rd American Association for the Study of Liver Diseases Annual Meeting (AASLD 2022). This is the world’s first clinical study reporting favorable safety and preliminary efficacy of an IAP antagonist for the treatment of patients with CHB.

REGENXBIO Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

REGENXBIO Logo
Published on :

REGENXBIO Inc. (Nasdaq: RGNX) today announced additional positive interim data from the ongoing Phase II ALTITUDE® trial of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery. The data were presented at the 55th Annual Retina Society meeting in Pasadena, CA by Lejla Vajzovic, MD, FASRS, Associate Professor of Ophthalmology and Director of Duke Vitreoretinal Fellowship Program, Vitreoretinal Surgery and Disease, Department of Ophthalmology, Duke University School of Medicine. RGX-314 is being investigated as a potential one-time gene therapy for the treatment of wet age-related macular degeneration, DR, and other chronic retinal conditions.

Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Published on :

Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the first patient has been dosed in Cohort 2 of its Phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD).

Cellular Biomedicine Group Announces FDA Clearance of IND Application for Novel TIL Therapy C-TIL051

Published on :

Cellular Biomedicine Group Inc. (CBMG or the “Company”), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced that the Food and Drug Administration (FDA) granted clearance of the Investigational New Drug (IND) application to proceed with Phase 1 clinical development of its novel Tumor Infiltrating Lymphocyte (TIL) product C-TIL051 for late-stage Non-Small Cell Lung Cancer (NSCLC) patients that are relapsed or refractory to anti-PD1 therapy.

BXP Life Sciences Expands with Montgomery County, Maryland Acquisition

Published on :

Boston Properties, Inc. (NYSE: BXP), the largest publicly traded developer, owner, and manager of Class A office properties in the United States, announced today that it has agreed to purchase the Shady Grove Bio+Tech Campus in Rockville, Maryland. The property includes seven existing buildings comprising approximately 435,000 square feet across 31 acres in the Shady Grove life sciences cluster, a highly desirable location for leading and emerging companies in the biotechnology sector.